New Genetic Markers for Prostate Cancer.

Abstract

Prostate cancer risk stratification based on conventional clinical and pathologic characteristics alone may misclassify a proportion of men at various stages of the disease process. Many gene-based assays have emerged in recent years that seek to improve the predictive accuracy in the prediagnostic and postdiagnostic settings. Following primary treatment failure, gene expression tests may offer improved stratification of individuals at risk for disease progression and inform refinements in the necessity of additional treatment. Unifying limitations among all novel gene-based tests are include clinical validation derived from historical cohorts and a dearth of empirical clinical effectiveness data.

DOI: 10.1016/j.ucl.2015.08.002

Cite this paper

@article{Leapman2016NewGM, title={New Genetic Markers for Prostate Cancer.}, author={Michael S. Leapman and Peter R. Carroll}, journal={The Urologic clinics of North America}, year={2016}, volume={43 1}, pages={7-15} }